Discriminatory Interest: None declared

THU0610  SERUM CALPROTECTIN LEVELS IN BEHÇET’S DISEASE: RELATIONSHIPS BETWEEN DISEASE ACTIVITY AND CLINICAL PARAMETERS


Background: Behçet’s disease (BD) is an inflammatory disease with chronic systemic vasculitis. The disease is characterized by attacks of oral and genital ulcers, skin lesions, arthritis, uveitis, and deep vein thrombosis. The main histopathologic feature is known to be vascular inflammatory changes. Calprotectin is expressed by granulocytes, monocytes, and endothelial cells, and produce an inflammatory response in human microvascular endothelial cells.

Objectives: The aim of this study was to evaluate serum calprotectin levels and their relationships with disease-related variables in patients with BD.

Methods: Forty-eight patients diagnosed with BD according to International Study Group of BD classification criteria and 22 demographically matched healthy control subjects participated in this study. Calprotectin levels were measured in blood samples from patients and controls. The disease durations of the patients were between 1 and 28 years. The Behçet’s Disease Current Activity Form (BDCAF), that scores the history of clinical features presenting during four weeks prior to the day of assessment, and Behçet’s Syndrome Activity Scale (BSAS) were used for the evaluation of disease activity.

Results: Mean serum calprotectin levels were significantly higher in patients with BD compared to the control group (60.6±43.8, 37.6±37.5, respectively; p=0.037) (Figure 1). Distribution of age (years; 40.6±12.9, 46.6±11.4, respectively; p=0.075) and sex (male; 62.5%, 45.5%, respectively, p=0.191) between these groups were similar. In the comparison of the calprotectin levels of the patients with or without the components of BD, we found significantly higher levels of calprotectin in patients with oral and genital ulceration versus without these involvements (Table 1). Since there were only 2 uveitis patients in this patient group, no calculations were made on uveitis. Serum calprotectin was significantly associated with BDCAF, BSAS, patient’s impression of disease activity, clinician’s impression of disease activity, ESR (Erythrocyte sedimentation rate) and CRP (C-reactive protein) (Table 2).

Conclusions: Our study demonstrated that serum calprotectin levels were significantly higher in patients with BD relative to the control group, and were significantly correlated with disease activity scores. The presence of a newly-developed genital and oral ulceration may be associated with higher levels of calprotectin. It can be concluded that serum calprotectin level seems to be a useful marker to monitor disease activity in BD.

Disclosure of Interest: None declared

THU0611  ANAKINRA TREATMENT IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: A SINGLE-CENTRE EXPERIENCE

B. Ergezen, S. Uğurboğlu, H. Özdogan. Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, University of Istanbul, Istanbul, Turkey

Background: Approximately 5 to 10% of FMF patients do not respond to colchicine treatment and/or intolerant to colchicine due to side effects. Several case reports and case series have pointed out the efficacy of IL-1 blockade in colchicine-resistant FMF subgroup.

Objectives: To review the patients followed in our centre with FMF who received anakinra, an anti-IL-1 receptor antagonist, because of insufficient colchicine response.

Methods: FMF patients who were treated with anakinra were retrospectively reviewed with regard to indication, effect on disease activity and acute phase response, adverse events. Patient global assessment was recorded before and after anakinra treatment.

Results: There were 48FMF patients with FMF who were treated with anakinra for various indications (colchicine resistant recurrent febrile attacks in 42, colchicine related side effects in 6). The mean age of the group was 31.8±9.2 years. The mean duration of the disease was 12.3±7.9 years. There were various co-existing pathologies among this study group like multiple sclerosis, anklylosing spondylitis, SLE, Behçet’s disease, low grade lymphoma, psoriasis, vasculitis and PAN. The mean colchicine dose was 2,13±0.51 mg/d. The mean duration of anakinra treatment was 14.47±10.8 months. Twenty seven patients reported no attacks after anakinra treatment whereas 10 patients reported at least 50% decrease in the attack frequency. There are 4 patients who were primarily unresponsive to the therapy, whereas in 5 patients response to therapy ameliorated during the course of the treatment. Mean patient global assessment decreased from 8.5±1.2 to 2.7±3.16 under anakinra treatment (p=0.001). Four patients had severe allergic reactions (severe disseminated rash in 1 patient and severe injection site reaction in 3 patients) and therefore the drug was stopped. Two patients had infections (one had genital warts and urinary tract infection, the other had sinusitis and folliculitis) and the treatment was terminated.

Disclosure of Interest: None declared

Table 1. Comparison of calprotectin levels of patients with or without the components of disease activity

<table>
<thead>
<tr>
<th>Component</th>
<th>(n) Calprotectin (ng/ml)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral ulceration</td>
<td>yes35 no14</td>
<td>73.2±46.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.4±32.3</td>
</tr>
<tr>
<td>Genital ulceration</td>
<td>yes3 no30</td>
<td>94.5±45.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>52.8±40.0</td>
</tr>
<tr>
<td>Erythema nodosum</td>
<td>yes5 no45</td>
<td>82.9±45.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>58.0±43.5</td>
</tr>
<tr>
<td>Skin pustules</td>
<td>yes16 no26</td>
<td>60.0±43.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>57.3±43.1</td>
</tr>
<tr>
<td>Arthritis</td>
<td>yes15 no33</td>
<td>62.1±44.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>57.5±43.1</td>
</tr>
<tr>
<td>Vascular activation</td>
<td>yes3 no30</td>
<td>59.5±52.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>60.9±42.4</td>
</tr>
</tbody>
</table>

Abstract THU0610 – Table 1. Comparison of calprotectin levels of patients with or without the components of disease activity

Table 2. Correlation between calprotectin level and disease characteristics in patients with BD

<table>
<thead>
<tr>
<th>Component</th>
<th>Calprotectin</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSAS</td>
<td>0.409</td>
<td>0.004</td>
</tr>
<tr>
<td>BDCAF</td>
<td>0.375</td>
<td>0.009</td>
</tr>
<tr>
<td>Patient’s impression of disease activity</td>
<td>0.401</td>
<td>0.005</td>
</tr>
<tr>
<td>Clinician’s impression of disease activity</td>
<td>0.385</td>
<td>0.007</td>
</tr>
<tr>
<td>ESR</td>
<td>0.440</td>
<td>0.002</td>
</tr>
<tr>
<td>CRP</td>
<td>0.312</td>
<td>0.031</td>
</tr>
</tbody>
</table>

Abstract THU0610 – Figure 1 Serum. calprotectin levels in BD and control groups

Abstract THU0611 – Figure 1
One of our patients reported that her psoriatic lesions got worse on anakinra. Forty one patients reported no adverse events during the treatment. Conclusions: Anakinra was effective in controlling the symptoms in colchicine-resistant FMF cases. It was also effective in FMF related amyloidosis. The major cause of treatment termination was injection site reactions. Anakinra seems to be an effective alternative in patients who have insufficient response to colchicine.

Disclosure of Interest: None declared

THU0612 Bone sarcoidosis: a retrospective multicenter study of 27 cases
C. Glanowski1, R. Mestiri2, L. Biâle3, T. Carmo4, L. Leroux5, D. Saadoun6, C. Chapelon-Aobic7, P. Cabou7, 1Rheumatology, 2Internal Medicine, Hôpital Bégin, Saint Mandé, Paris, France

Background: Studies on bone involvement of sarcoidosis (BS) are scarce.

Objectives: To analyse in depth main features, treatments and follow up of patients presenting a BS.

Methods: Among 926 patients with a proved sarcoidosis from four tertiary hospitals in Paris (France) seen between 2000 and 2015, all cases of BS were retrospectively analysed for demography, clinical features, biological tests and imaging results. Inclusion criteria were a) a bone biopsy with epithelioid granuloma and no casein necrosis, or b) radiological evidence of BS, after exclusion of other diagnoses.

Results: 27 out 926 (2.9%) sarcoidosis patients fulfilled inclusion criteria for BS. Most patients were Caucasians (56%), M:F sex ratio 1.5, 30% were active smokers, mean age at sarcoidosis diagnosis was 39±12 years and at BS diagnosis 43±11 years. Extra-osseous involvement of sarcoidosis was found in lymph nodes (93%), lungs (78%), skin (52%), CNS (33%), ENT (33%), and heart (19%). BS was asymptomatic in 15/27 (56%) patients i.e. bone pain (15/15), local inflammation (5/15), bone deformation (3/15), arthritis (4/15), and myalgia (5/15). BS was never the revealing symptom of sarcoidosis. BS was more frequently symptomatic when it was a Perthes-Jüngling ostitis and an appendicular skeleton involvement. On imaging exams, BS lesions were found at the spine skeleton alone (14/27, 52%), appendicular skeleton alone (10/27, 37%) or both (3/27, 11%). BS lesions had an aspect of pseudo-metastasis (59%), micro-cysts (Perthes-Jungling, 37%) or Paget disease (4%). Bone lesion was unique in 22% and 26% of patients had more than 10 lesions. When a bone biopsy was done it was always confirmed the diagnosis (n=9), in all other cases extra-osseous biopsies confirmed the diagnosis of sarcoidosis. Nine patients received a treatment for BS, i.e. prednisone (n=8, 0.25–1 mg/kg/day), hydroxychloroquine (n=8), and methotrexate (n=5). Response to treatment was complete (n=3), partial (n=4) or nul (n=2). Of note, 21 out of 27 patients received an immunosuppressant for a severe form of systemic sarcoidosis (n=11) or for a steroid-sparing effect (n=10). A relapse of BS was noted in 13 patients, with a mean number of relapse of 2.1–24. After a mean follow up of 49 months, BS was in complete remission (8/27, 30%), partial remission (16/27, 59%) or remained active (3/27, 11%).

Conclusions: Bone involvement remains a rare manifestation of sarcoidosis. It was symptomatic in 56% of patients, mainly when Perthes-Jüngling ostitis and appendicular skeleton involvement were present. Extra-osseous involvement of sarcoidosis were always present at the time of BS diagnosis. Treatment remained difficult with frequent relapses.

Disclosure of Interest: None declared

THU0613 The frequency and characteristics of headache in Behcet disease and its evaluation by transcranial doppler ultrasonography
F. Salgía1, D. Işıkdriver Cansu2, N. Uzuner3, C. Korkmaz4, 1Internal Medicine, Endocrinology, Kent Hospital, İzmir, 2Internal Medicine, Rheumatology, 3Neurology, Eskişehir Osmangazi University, Eskişehir, Turkey

Background: Behcet’s disease (BD) is a multisystem vasculitis disease and the most often neurologic manifestation of BD is headache. Transcranial Doppler ultrasonography (TCD) is a test which used for evaluating the changes in blood flow velocity developed against visual stimulation. It is not well known TCD findings in BD patients who suffered from headache.

Objectives: To evaluate the frequency and the types of headache and to investigate cerebral reactivity by TCD in BD patients.

Methods: 113 patients with BD diagnosed based on diagnostic criteria of BD by ISG and 40 healthy individuals were included in the study. The patients with BD who had neurological involvement were not included to the study. Headache type was specified by a specialist neurologist according to International classification of the headache disorders society criteria. TCD was applied to 62 patients with BD and 40 healthy individuals. TCD results were evaluated by a specialist neurologist.

Results: Headache was determined in 89 (78.8%) patients with BD. It was statistically significant compared to HC group (60%, p<0.03). 48 of 89 BD patients had tension type of headache and 33 of them had migraineous type. No significant difference was found between BD and HC patients and HC group in terms of cerebral reactivity by TCD. Low pulsatility index for both the right side and the left side were noted in BD patients suffering from headache compared to BD patients not having headache (p<0.006, p<0.003). No significant differences were found between tension type and migraineous type of headache in terms of TCD parameters.

Conclusions: Headache is common in BD patients, but cerebral reactivity is maintained.

Disclosure of Interest: None declared

THU0614 Interstitial lung disease in patients with antisynthetase syndrome and anti-RO52 antibodies positive
C. Aguilar Cres1, A. Ruiz Román1, L. Méndez Díaz2, G. Morote Ibarrola3, N. Barrios Purita1, M. A. Montes Cao1, J. A. Rodriguez Portal4, 1Rheumatology, University Hospital Virgen del Rocio, 2Rheumatology, Quirón Sacred Heart Hospital, 3Immunology, 4Pneumology, University Hospital Virgen del Rocio, Seville, Spain

Background: Antisynthetase syndrome (ASS) is characterised by the presence of myositis, arthritis, interstitial lung disease (ILD), fever, Raynaud’s phenomenon and mechanic’s hand. It is in the presence of antisynthetase autoantibodies (AA), the most frequent being anti-Jo1, anti-PL7 and anti-PL12. An association between ASS and anti-RO52 with increased ILD has been described and it is believed that the presence of both antibodies is accompanied by a more severe ILD.

Objectives: To describe the clinical and analytical characteristics of a cohort of patients with ASS. To analyse the lung involvement in this type of patient to determine the possible relationship between the different subtypes of ILD and the presence of anti-RO52.

Methods: Retrospective descriptive study of patients treated in our Hospital (2006–2017), with AA and at least 2 clinical characteristics. The data was obtained through the review of medical records. Variables analysed: age, sex, age, smoking, clinical presentation, diagnosis of ASS, associated neoplasia and paraneoplastic syndrome (PS)(neoplasia 3 years before or after the diagnosis of ASS), muscle enzymes (CK and aldolase), autoimmunity, glucocorticoids (GC), immunosuppressants (IS), diagnosis of ILD, HRCT patterns, Oxidation Reduction Potential (Computed Tomography) and respiratory function tests (RFT) at the beginning of ILD.

Results: We included 27 patients (20 women), mean age 61±13 years. 7.4% smokers and 18.5% ex-smokers. 88.8% were anti-Jo1,7.4% anti-PL12 and 3.7% anti-PL7. Anti-RO52 present in 18 patients. The most common clinical presentation:ILD 88% (59% had Ro52), followed by myositis 85% (40% are dermatomyositis, 35% polymyositis). The arthritis 81%, mechanic’s hand 51%, fever 37% and Raynaud’s phenomenon 25%. The classic triad (arthritis, myositis, ILD) was present in 16 patients. Three patients presented neoplasia in the course of the disease, being identified as PS. Elevation of CK in 70% and aldolase in 74%, 96% of patients have been treated with GC and IS. The HRCT patterns were non-specific interstitial pneumonia (NSIP)(66%), usual interstitial pneumonia (UIP) (29%),organised cryptogenic pneumonitis (OP)(4%), baseline RFT were performed in 19 patients. Diagnosis of ASS and ILD, both entities appear at the same time in 6 patients, in 3 patients the ILD appears before and in 14 after. In these, the median duration (range) of the ASS until the diagnosis of ILD was 1 year (0–1).

There is no relationship between the HRCT and anti-RO52 patterns (chi-square considering the exact distribution p=0.892), nor between the ILD and anti-RO52 (Fisher exact test p=0.999).

Conclusions: Our results, in general, agree with what is published in the literature. Three patients have an uncommon presentation of ASS, with a diagnosis of ILD prior to myopathy (in most of the published cases, myositis precedes or coincides with the onset of ILD), and it is important to include ASS in the differential diagnosis of ILD. In our cohort, the association between ILD and anti-RO52 has not been demonstrated, nor among the different subtypes of ILD to Ro52. Therefore, prospective studies with a greater number of patients are necessary to define Ro52’s role in the development of ILD in ASS.

Disclosure of Interest: None declared